|
|
|
|
| Advertisement |
 |
|
|
|
|
| Advertisement |
Managing Global Regulatory Complexity: Clinical Trial Transparency, Reporting and Real-time Data Driven Compliance
Wednesday, August 14, 2019 at 12pm EDT | 9am PDT | 5pm BST | 6pm CEST
 Register Now
|
|
| Global |
|
|
| Special Feature |
 |
|
Pharm Exec's Top 50 Companies 2019 |
Our 19th annual listing reveals some interesting maneuvering of ranks, as companies focus on diversification, big-brand expansions, and positioning a new wave of products to compete in an advancing but complex future treatment market
… /Read More/ |
|
|
|
| Industry update |
| //RefleXionTM Medical (Hayward, CA) announced that Thorsten Melcher, Ph.D., has joined as Chief Business Officer.
//
Mereo BioPharma (London, UK and Redwood City, CA) announced the
appointment of Richard Francis as Head of Pharmaceutical Development, effective August 1, 2019.
//
Exactus (Delray Beach, FL) appointed Kenneth E. Puzder as Chief Financial Officer.
//
Aptinyx (Evanston, IL) announced that Joseph Moskal, Ph.D., the company's Chief Scientific Officer, is retiring to focus on his academic work at Northwestern University. Dr. Moskal will continue his close association with Aptinyx in a senior advisory capacity.
//
Soligenix (Princeton, NJ) recruited Diane L. Parks to its Board of Directors.
//
Ziopharm Oncology announced that the National Cancer Institute's Drew Deniger, Ph.D., has been appointed to lead the company's program to genetically modify T cells to express neoantigen-specific T-cell receptors, effective July 29, 2019.
//
Andrew Bast joined Greater Than One, a New York-based healthcare marketing agency, as Chief Strategy Officer.//
|
|
|
|
|
|
|
|
|
